Genetic polymorphisms and response to medications for alcohol use disorders: A systematic review and meta-analysis

Pharmacogenomics

Volumn 15, Issue 13, 2014, Pages 1687-1700

  Jonas, Daniel E ^a,b   Amick, Halle R ^b   Feltner, Cynthia ^a,b   Wines, Roberta ^b   Shanahan, Ellen ^b   Rowe, Cassandra J ^c   Garbutt, James C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

alcohol; alcohol dependence; alcohol use disorder; naltrexone; opioid receptor; OPRM1; pharmacogenomics; polymorphism; systematic review

Indexed keywords

ACAMPROSATE; DELTA OPIATE RECEPTOR; DISULFIRAM; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; KAINIC ACID RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALMEFENE; NALTREXONE; OLANZAPINE; PLACEBO; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SERTRALINE; TOPIRAMATE; TRANSCRIPTION FACTOR GATA; OPRM1 PROTEIN, HUMAN;

ALCOHOL ABSTINENCE; ALCOHOL USE DISORDER; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; META ANALYSIS; MU OPIATE RECEPTOR GENE; PATIENT COUNSELING; PHARMACOGENETICS; RELAPSE; SYSTEMATIC REVIEW; ALCOHOL-INDUCED DISORDERS; GENETICS;

ALCOHOL-INDUCED DISORDERS; GENOTYPE; HUMANS; NALTREXONE; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 84913589676     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.121     Document Type: Article

References (46)

1. Mann K, Schafer DR, Langle G, Ackermann K, Croissant B. The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction 100(6), 797-805 (2005).
2. Norstrom T. Per capita alcohol consumption and all-cause mortality in Canada, 1950-98. Addiction 99(10), 1274-1278 (2004).
3. Rivara FP, Garrison MM, Ebel B, McCarty CA, Christakis DA. Mortality attributable to harmful drinking in the United States, 2000. J. Stud. Alcohol 65(4), 530-536 (2004).
4. Jonas DE, Amick HR, Feltner C et al. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings. Comparative Effectiveness Review No. 134. (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center under Contract No. HHSA290201200007I-HHSA29032002T.) Agency for Healthcare Research and Quality. Rockville, MD, USA. www.effectivehealthcare.ahrq.gov/reports/final.cfm
5. Schuckit MA. Alcohol-use disorders. Lancet 373(9662), 492-501 (2009).
6. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev. Med. 38(5), 613-619 (2004).
7. Alcohol-attributable deaths and years of potential life lost-United States, 2001. MMWR Morb. Mortal. Wkly Rep. 53(37), 866-870 (2004).
8. Cherpitel CJ, Ye Y. Alcohol-attributable fraction for injury in the U.S. general population: data from the 2005 National Alcohol Survey. J. Stud. Alcohol Drugs 69(4), 535-538 (2008).
9. Jonas DE, Amick HR, Feltner C et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311(18), 1889-1900 (2014).
10. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 12, CD001867 (2010).
11. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst. Rev. 9, CD004332 (2010).
12. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin. Exp. Res. 25(9), 1335-1341 (2001).
13. Anton RF, Oroszi G, O'Malley S et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65(2), 135-144 (2008).
14. Kranzler HR, Armeli S, Covault J, Tennen H. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict. Biol. 18(1), 193-201 (2013).
15. O'Malley SS, Robin RW, Levenson AL et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin. Exp. Res. 32(7), 1271-1283 (2008).
16. Rubio G, Ponce G, Jiménez-Arriero MA et al. Polymorphism for m-opioid receptor (+118) as a prognostic variable of naltrexone in alcohol dependence treatment: preliminary results. Eur. Neuropsychopharmacol. 12(Suppl. 3), 397 (2002).
17. Evidence-based Practice Center Systematic Review Protocol. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings (2013). http://effectivehealthcare.ahrq.gov/ehc/products/477/1483/Alcohol-misuse-drug-therapy-140326. pdf
18. AHRQ Effective Health Care Program: Search for Research Summaries, Reviews, and Reports. www.effectivehealthcare.ahrq.gov/reports/final.cfm
19. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Agency for Healthcare Research and Quality, Rockville, MD, USA (2008). www.effectivehealthcare.ahrq.gov/ehc/products/60/318/CER-Methods-Guide-140109.pdf
20. Viswanathan M, Ansari MT, Berkman ND et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. March 2012. AHRQ Publication No. 12-EHC047-EF. www.effectivehealthcare.ahrq.gov/ehc/products/322/998/MethodsGuideforCERs-Viswanathan-IndividualStudies. pdf
21. Jonas DE, Wilt TJ, Taylor BC, Wilkins TM, Matchar DB. AHRQ Publication No. 12-EHC083-EF. Chapter 11, Methods Guide for Medical Test Reviews. AHRQ Publication No. 12-EHC017 (2012). www.effectivehealthcare.ahrq.gov/ehc/products/246/558/Methods-Guide-for-Medical-Test-Reviews-Full-Guide-20120530.pdf
22. Santaguida PL, Riley CR, Matchar DB. Assessing risk of bias as a domain of quality in medical test studies. AHRQ Publication No. 12-EHC077-EF. Chapter 5, Methods Guide for Medical Test Reviews. AHRQ Publication No. 12-EHC017 (June 2012). www.effectivehealthcare.ahrq.gov/ehc/products/246/558/Methods-Guide-for-Medical-Test-Reviews-Full-Guide-20120530.pdf
23. West SL, Gartlehner G, Mansfield AJ et al. Comparative effectiveness review methods: clinical heterogeneity. Methods Research Report (2010). www.effectivehealthcare.ahrq.gov/ehc/products/93/533/Clinical-Heterogeneity-Revised-Report.pdf
24. Sutton AJ, Abrams KR, Jones DR et al. Methods for Meta-Analysis in Medical Research (Wiley Series in Probability and Statistics-Applied Probability and Statistics Section). Wiley, London, UK (2000).
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539-1558 (2002).
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003).
27. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8), 1546-1552 (2003).
28. Chen AC, Morgenstern J, Davis CM, Kuerbis AN, Covault J, Kranzler HR. Variation in mu-opioid receptor gene as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort. J. Alcohol Drug Depend. 1(1), 101 (2013).
29. Coller JK, Cahill S, Edmonds C et al. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet. Genomics 21(12), 902-905 (2011).
30. Gelernter J, Gueorguieva R, Kranzler HR et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin. Exp. Res. 31(4), 555-563 (2007).
31. Kim SG, Kim CM, Choi SW et al. A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201(4), 611-618 (2009).
32. Arias AJ, Armeli S, Gelernter J et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin. Exp. Res. 32(7), 1159-1166 (2008).
33. Florez G, Saiz P, Garcia-Portilla P et al. Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. Alcohol Alcohol. 43(5), 516-522 (2008).
34. Hutchison KE, Ray L, Sandman E et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31(6), 1310-1317 (2006).
35. Kiefer F, Witt SH, Frank J et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 11(5), 368-374 (2011).
36. Kranzler HR, Armeli S, Feinn R, Tennen H, Gelernter J, Covault J. GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink. Int. J. Neuropsychopharmacol. 17(10), 1549-1556 (2014).
37. Kranzler HR, Armeli S, Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol Clin. Exp. Res. 36(4), 739-744 (2012).
38. Mutschler J, Abbruzzese E, Witt SH et al. Functional polymorphism of the dopamine β-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J. Clin. Psychopharmacol. 32(4), 578-580 (2012).
39. Morgenstern J, Kuerbis AN, Chen AC, Kahler CW, Bux DA Jr, Kranzler HR. A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men. J. Consult. Clin. Psychol. 80(5), 863-875 (2012).
40. Oroszi G, Anton RF, O'Malley S et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin. Exp. Res. 33(3), 383-393 (2009).
41. Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict. Biol. 17(3), 505-512 (2012).
42. Polich JM, Armor DJ, Braiker HB. Stability and change in drinking patterns. In: The Course of Alcoholism: Four Years After Treatment. 159-200 (1980). www.rand.org/content/dam/rand/pubs/reports/2006/R2433.pdf
43. Kissin B, Charnoff SM, Rosenblatt SM. Drug and placebo responses in chronic alcoholics. Psychiatr. Res. Rep. 24, 44-60 (1968).
44. Babor TF, Steinberg K, Anton R, Del Boca F. Talk is cheap: measuring drinking outcomes in clinical trials. J. Stud. Alcohol 61(1), 55-63 (2000).
45. Del Boca FK, Noll JA. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 95(Suppl. 3), S347-S360 (2000).
46. Johnson BA, Ait-Daoud N, Seneviratne C et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168(3), 265-275 (2011).